Zevra Therapeutics. has been granted a patent for novel prodrugs and compositions of dextrorphan, which include oxoacids, polyethylene glycols, and vitamin compounds chemically conjugated to dextrorphan. The patent outlines a specific compound with a defined general formula. GlobalData’s report on Zevra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zevra Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Zevra Therapeutics's grant share as of July 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Novel prodrugs and compositions of dextrorphan
The granted patent US12012384B2 introduces a novel compound characterized by a specific general formula. The claims detail the structural components of the compound, emphasizing the presence or absence of certain elements, such as L2 and Y2, and the configuration of M, which can include a carbon chain represented as —(CR3R4)q. Additionally, the claims specify that G2 must include at least one oxoacid, with a range for the variable m set between 1 and 3. This framework establishes the foundational structure of the compound, allowing for variations in its chemical composition.
Further specificity is provided in the claims, particularly in claim 3, which identifies acetic acid as a potential oxoacid component. Claim 4 narrows the focus to a particular compound, N-(acetyl-OCH2)-dextrorphanium, detailing its structural formula. This compound exemplifies the application of the general formula outlined in the earlier claims, showcasing the potential for practical use in various chemical or pharmaceutical contexts. The patent thus delineates a clear and structured approach to the development of this compound, highlighting its unique characteristics and potential applications.
To know more about GlobalData’s detailed insights on Zevra Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
